Type 2 diabetes mellitus.
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R.
Nat Rev Dis Primers. 2015 Jul 23;1:15019. doi: 10.1038/nrdp.2015.19.
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
GRADE Study Research Group; Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, Fortmann SP, Green JB, Kahn SE, Kirkman MS, Krause-Steinrauf H, Larkin ME, Phillips LS, Pop-Busui R, Steffes M, Tiktin M, Tripputi M, Wexler DJ, Younes N.
N Engl J Med. 2022 Sep 22;387(12):1075-1088. doi: 10.1056/NEJMoa2200436.
Genetics of diabetes-associated microvascular complications.
Lyssenko V, Vaag A.
Diabetologia. 2023 Sep;66(9):1601-1613. doi: 10.1007/s00125-023-05964-x. Epub 2023 Jul 14.
Approach to the Patient with MODY-Monogenic Diabetes.
Broome DT, Pantalone KM, Kashyap SR, Philipson LH.
J Clin Endocrinol Metab. 2021 Jan 1;106(1):237-250. doi: 10.1210/clinem/dgaa710.
Cardiac Autonomic Neuropathy in Diabetes Mellitus.
Agashe S, Petak S.
Methodist Debakey Cardiovasc J. 2018 Oct-Dec;14(4):251-256. doi: 10.14797/mdcj-14-4-251.
Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes.
Hicks CW, Selvin E.
Curr Diab Rep. 2019 Aug 27;19(10):86. doi: 10.1007/s11892-019-1212-8.
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J, Jeon M, Brooks A.
Am J Health Syst Pharm. 2019 Oct 15;76(21):1739-1748. doi: 10.1093/ajhp/zxz179.
Mesenchymal Stem Cell Exosomes as a New Strategy for the Treatment of Diabetes Complications.
Xiong J, Hu H, Guo R, Wang H, Jiang H.
Front Endocrinol (Lausanne). 2021 Apr 29;12:646233. doi: 10.3389/fendo.2021.646233. eCollection 2021.
Diabetic microvascular complications are associated with left atrial structural alterations in asymptomatic type 2 diabetes patients: A cross-sectional study.
Gong M, Xu M, Meng J, Jiang S, Jiang X.
J Diabetes Complications. 2023 Jan;37(1):108361. doi: 10.1016/j.jdiacomp.2022.108361. Epub 2022 Nov 30.
Understanding the drivers and consequences of early-onset type 2 diabetes.
Lim LL, Jones S, Cikomola JC, Hivert MF, Misra S.
Lancet. 2025 Jun 28;405(10497):2327-2340. doi: 10.1016/S0140-6736(25)01012-8. Epub 2025 Jun 23.
